| 摘要 |
Disclosed is the use of a DPPIV inhibitor (such as glutaminyl thiazolidine based DPIV inhibitors, sitagliptin, vildagliptin, saxagliptin, denagliptin or alogliptin), in combination with metformin or a thiazolidinedione (such as troglitazone, ciglitazone, pioglitazone, englitazone or rosiglitazone) in the manufacture of a medicament for the treatment of type 2 diabetes in a human, wherein the DPIV inhibitor in combination with metformin or a thiazolidinedione is a first-line therapy for the treatment of type 2 diabetes in a human, wherein the human has not previously been treated with a pharmaceutical antidiabetic agent. |
